MedPath

Comparative Study of Intravenous Single Doses of Palonosetron (PALO) With Granisetron Hydrochloride as a Control in Patients Receiving Highly Emetogenic Chemotherapy.

Phase 3
Conditions
Acute and delayed nausea and vomiting
Registration Number
JPRN-jRCT2080220284
Lead Sponsor
Taiho Pharmaceutical Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Acute and delayed nausea and vomiting induced by highly emetogenic chemotherapy.

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath